MetaboLights MTBLS1122 - GNPS Sex-Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype
Ontology highlight
ABSTRACT: Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher prevalence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes amongst CRC patients. Aberrant metabolism is a feature of CRC, but it is not known if sex-differences exist. Metabolomics of patient colon tissues (n=236) revealed widespread sex-differences in metabolism depending on tumor location and stage. Tumors from women with RCC were nutrient-deplete, showing enhanced energy production towards asparagine synthesis, and an increase in amino acid uptake. Gene expression data revealed an association between high asparagine synthase expression and poorer overall survival in women with CRC. This is the first study to show sex-differences in tumor tissue metabolism for CRC patients revealing a nutrient-deplete subtype in women with RCC. The results therefore have implications for tumor progression and therapeutic response in women with RCC. Linked Studies: UPLC-MS HILIC POS assay is reported in MTBLS1122 UPLC-MS HILIC NEG assay is reported in MTBLS1124 UPLC-MS RP POS assay is reported in MTBLS1129 UPLC-MS RP NEG assay is reported in MTBLS1130
INSTRUMENT(S): Xevo G2-S QTof|1002276
ORGANISM(S): Homo Sapiens|9606
SUBMITTER: 
Yuping Cai
PROVIDER: MSV000085874 | GNPS | Sat Aug 01 12:01:00 BST 2020
REPOSITORIES: GNPS
Similar Datasets
Project description:<p>Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher prevalence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes amongst CRC patients. Aberrant metabolism is a feature of CRC, but it is not known if sex-differences exist. Metabolomics of patient colon tissues (n=236) revealed widespread sex-differences in metabolism depending on tumor location and stage. Tumors from women with RCC were nutrient-deplete, showing enhanced energy production towards asparagine synthesis, and an increase in amino acid uptake. Gene expression data revealed an association between high asparagine synthase expression and poorer overall survival in women with CRC. This is the first study to show sex-differences in tumor tissue metabolism for CRC patients revealing a nutrient-deplete subtype in women with RCC. The results therefore have implications for tumor progression and therapeutic response in women with RCC.</p><p><br></p><p>Linked Studies:</p><p>UPLC-MS HILIC POS assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1122" target="_blank">MTBLS1122</a></p><p>UPLC-MS HILIC NEG assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1124" target="_blank">MTBLS1124</a></p><p>UPLC-MS RP POS assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1129" target="_blank">MTBLS1129</a></p><p>UPLC-MS RP NEG assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1130" target="_blank">MTBLS1130</a></p>
2020-08-01 | MSV000085884 | GNPS
Project description:<p>Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher prevalence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes amongst CRC patients. Aberrant metabolism is a feature of CRC, but it is not known if sex-differences exist. Metabolomics of patient colon tissues (n=236) revealed widespread sex-differences in metabolism depending on tumor location and stage. Tumors from women with RCC were nutrient-deplete, showing enhanced energy production towards asparagine synthesis, and an increase in amino acid uptake. Gene expression data revealed an association between high asparagine synthase expression and poorer overall survival in women with CRC. This is the first study to show sex-differences in tumor tissue metabolism for CRC patients revealing a nutrient-deplete subtype in women with RCC. The results therefore have implications for tumor progression and therapeutic response in women with RCC.</p><p><br></p><p>Linked Studies:</p><p>UPLC-MS HILIC POS assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1122" target="_blank">MTBLS1122</a></p><p>UPLC-MS HILIC NEG assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1124" target="_blank">MTBLS1124</a></p><p>UPLC-MS RP POS assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1129" target="_blank">MTBLS1129</a></p><p>UPLC-MS RP NEG assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1130" target="_blank">MTBLS1130</a></p>
2020-08-01 | MSV000085877 | GNPS
Project description:<p>Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher prevalence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes amongst CRC patients. Aberrant metabolism is a feature of CRC, but it is not known if sex-differences exist. Metabolomics of patient colon tissues (n=236) revealed widespread sex-differences in metabolism depending on tumor location and stage. Tumors from women with RCC were nutrient-deplete, showing enhanced energy production towards asparagine synthesis, and an increase in amino acid uptake. Gene expression data revealed an association between high asparagine synthase expression and poorer overall survival in women with CRC. This is the first study to show sex-differences in tumor tissue metabolism for CRC patients revealing a nutrient-deplete subtype in women with RCC. The results therefore have implications for tumor progression and therapeutic response in women with RCC.</p><p><br></p><p>Linked Studies:</p><p>UPLC-MS HILIC POS assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1122" target="_blank">MTBLS1122</a></p><p>UPLC-MS HILIC NEG assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1124" target="_blank">MTBLS1124</a></p><p>UPLC-MS RP POS assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1129" target="_blank">MTBLS1129</a></p><p>UPLC-MS RP NEG assay is reported in <a href="https://www.ebi.ac.uk/metabolights/MTBLS1130" target="_blank">MTBLS1130</a></p>
2020-08-01 | MSV000085889 | GNPS
Project description:<p>Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic target for cancer. We propose that metabolic subphenotypes exist between CRCs due to intertumoral molecular and genomic variation, and differences in environmental milieu of the colon which vary between the sexes. Metabolomics analysis of patient colon tumors (n = 197) and normal tissues (n = 39) revealed sex-specific metabolic subphenotypes dependent on anatomic location. Tumors from women with RCC were nutrient-deplete, showing enhanced energy production to fuel asparagine synthesis and amino acid uptake. The clinical importance of our findings were further investigated in an independent data set from The Cancer Genomic Atlas, and demonstrated that high asparagine synthetase (ASNS) expression correlated with poorer survival for women. This is the first study to show a unique, nutrient-deplete metabolic subphenotype in women with RCC, with implications for tumor progression and outcomes in CRC patients.</p><p><br></p><p><strong>UPLC-MS HILIC POS assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1122' rel='noopener noreferrer' target='_blank'><strong>MTBLS1122</strong></a>.</p><p><strong>UPLC-MS HILIC NEG assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1124' rel='noopener noreferrer' target='_blank'><strong>MTBLS1124</strong></a>.</p><p><strong>UPLC-MS RP POS assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1129' rel='noopener noreferrer' target='_blank'><strong>MTBLS1129</strong></a>.</p><p><strong>UPLC-MS RP NEG assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1130' rel='noopener noreferrer' target='_blank'><strong>MTBLS1130</strong></a>.</p>
2020-03-19 | MTBLS1130 | MetaboLights
Project description:<p>Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic target for cancer. We propose that metabolic subphenotypes exist between CRCs due to intertumoral molecular and genomic variation, and differences in environmental milieu of the colon which vary between the sexes. Metabolomics analysis of patient colon tumors (n = 197) and normal tissues (n = 39) revealed sex-specific metabolic subphenotypes dependent on anatomic location. Tumors from women with RCC were nutrient-deplete, showing enhanced energy production to fuel asparagine synthesis and amino acid uptake. The clinical importance of our findings were further investigated in an independent data set from The Cancer Genomic Atlas, and demonstrated that high asparagine synthetase (ASNS) expression correlated with poorer survival for women. This is the first study to show a unique, nutrient-deplete metabolic subphenotype in women with RCC, with implications for tumor progression and outcomes in CRC patients.</p><p><br></p><p><strong>UPLC-MS HILIC POS assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1122' rel='noopener noreferrer' target='_blank'><strong>MTBLS1122</strong></a>.</p><p><strong>UPLC-MS HILIC NEG assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1124' rel='noopener noreferrer' target='_blank'><strong>MTBLS1124</strong></a>.</p><p><strong>UPLC-MS RP POS assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1129' rel='noopener noreferrer' target='_blank'><strong>MTBLS1129</strong></a>.</p><p><strong>UPLC-MS RP NEG assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1130' rel='noopener noreferrer' target='_blank'><strong>MTBLS1130</strong></a>.</p>
2020-03-19 | MTBLS1129 | MetaboLights
Project description:<p>Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic target for cancer. We propose that metabolic subphenotypes exist between CRCs due to intertumoral molecular and genomic variation, and differences in environmental milieu of the colon which vary between the sexes. Metabolomics analysis of patient colon tumors (n = 197) and normal tissues (n = 39) revealed sex-specific metabolic subphenotypes dependent on anatomic location. Tumors from women with RCC were nutrient-deplete, showing enhanced energy production to fuel asparagine synthesis and amino acid uptake. The clinical importance of our findings were further investigated in an independent data set from The Cancer Genomic Atlas, and demonstrated that high asparagine synthetase (ASNS) expression correlated with poorer survival for women. This is the first study to show a unique, nutrient-deplete metabolic subphenotype in women with RCC, with implications for tumor progression and outcomes in CRC patients.</p><p><br></p><p><strong>UPLC-MS HILIC POS assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1122' rel='noopener noreferrer' target='_blank'><strong>MTBLS1122</strong></a>.</p><p><strong>UPLC-MS HILIC NEG assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1124' rel='noopener noreferrer' target='_blank'><strong>MTBLS1124</strong></a>.</p><p><strong>UPLC-MS RP POS assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1129' rel='noopener noreferrer' target='_blank'><strong>MTBLS1129</strong></a>.</p><p><strong>UPLC-MS RP NEG assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1130' rel='noopener noreferrer' target='_blank'><strong>MTBLS1130</strong></a>.</p>
2020-03-19 | MTBLS1122 | MetaboLights
Project description:<p>Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic target for cancer. We propose that metabolic subphenotypes exist between CRCs due to intertumoral molecular and genomic variation, and differences in environmental milieu of the colon which vary between the sexes. Metabolomics analysis of patient colon tumors (n = 197) and normal tissues (n = 39) revealed sex-specific metabolic subphenotypes dependent on anatomic location. Tumors from women with RCC were nutrient-deplete, showing enhanced energy production to fuel asparagine synthesis and amino acid uptake. The clinical importance of our findings were further investigated in an independent data set from The Cancer Genomic Atlas, and demonstrated that high asparagine synthetase (ASNS) expression correlated with poorer survival for women. This is the first study to show a unique, nutrient-deplete metabolic subphenotype in women with RCC, with implications for tumor progression and outcomes in CRC patients.</p><p><br></p><p><strong>UPLC-MS HILIC POS assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1122' rel='noopener noreferrer' target='_blank'><strong>MTBLS1122</strong></a>.</p><p><strong>UPLC-MS HILIC NEG assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1124' rel='noopener noreferrer' target='_blank'><strong>MTBLS1124</strong></a>.</p><p><strong>UPLC-MS RP POS assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1129' rel='noopener noreferrer' target='_blank'><strong>MTBLS1129</strong></a>.</p><p><strong>UPLC-MS RP NEG assay</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS1130' rel='noopener noreferrer' target='_blank'><strong>MTBLS1130</strong></a>.</p>
2020-03-19 | MTBLS1124 | MetaboLights
Project description:<p>Francesca Petralia,Nicole Tignor,Boris Reva, et al., (2020) <a href="https://www.cell.com/cell/fulltext/S0092-8674(20)31451-3" target="_blank">Cell 183, 1962-1985</a></p><p>We report a comprehensive proteogenomics analysis, including whole-genome sequencing, RNA sequencing, and proteomics and phosphoproteomics profiling, of 218 tumors across 7 histological types of childhood brain cancer: low-grade glioma (n = 93), ependymoma (32), high-grade glioma (25), medulloblastoma (22), ganglioglioma (18), craniopharyngioma (16), and atypical teratoid rhabdoid tumor (12). Proteomics data identify common biological themes that span histological boundaries, suggesting that treatments used for one histological type may be applied effectively to other tumors sharing similar proteomics features. Immune landscape characterization reveals diverse tumor microenvironments across and within diagnoses. Proteomics data further reveal functional effects of somatic mutations and copy number variations (CNVs) not evident in transcriptomics data. Kinase-substrate association and co-expression network analysis identify important biological mechanisms of tumorigenesis. This is the first large-scale proteogenomics analysis across traditional histological boundaries to uncover foundational pediatric brain tumor biology and inform rational treatment selection.</p><p>The Children's Brain Tumor Network (CBTN) and the Pacific Pediatric Neuro-Oncology Consortia (PNOC) are collaborative research consortia focused on identifying therapies for children with brain tumors (<a href="https://cbttc.org" target="_blank">https://cbttc.org</a>). The consortia have contributed a <a href="https://kidsfirstdrc.org/support/studies-and-access/#SD_BHJXBDQK" target="_blank">Pediatric Brain Tumor Atlas (PBTA) dataset</a>, a cohort of 991 brain tumor subject clinical data, with associated whole genome sequencing and RNAseq hosted by the Gabriella Miller Kids First Data Resource (<a href="https://kidsfirstdrc.org/" target="_blank">kidsfirstdrc.org</a>) as part of the Gabriella Miller Kids First Pediatric Research Program (Kids First). Kids First is a Pan NIH Common Fund program dedicated to the development of large-scale data resources to help researchers uncover new insights into the biology of childhood cancer and structural birth defects (<a href="https://commonfund.nih.gov/KidsFirst" target="_blank">https://commonfund.nih.gov/KidsFirst</a>).</p><p>Mass Spectrometry raw data generation along with preliminary analyses were performed at the <a href="https://tcmp.hms.harvard.edu/" target="_blank">Thermo Fisher Scientific Center for Multiplexed Proteomics (TCMP)</a>, Harvard Medical School (HMS) under the direction of <a href="https://cellbio.med.harvard.edu/people/faculty/gygi" target="_blank">Prof. Steven Gygi</a>. Samples were prepared using the streamline (SL)-TMT protocol (<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994137/" target="_blank">Navarrete-Perea et al., 2018</a>) and MS analysis was performed using the SPS-MS3 strategy (<a href="https://www.nature.com/articles/nmeth.1714" target="_blank">Ting et al., 2011</a>) developed in the <a href="https://gygi.med.harvard.edu/" target="_blank">Gygi lab</a>. Additional data analyses from the CPTAC Common Data Analysis Pipeline (<a href="https://www.ncbi.nlm.nih.gov/pubmed/26860878" target="_blank">Rudnick et al., 2016</a>) and from the University of Michigan Proteomics and Integrative Bioinformatics Laboratory (<a href="https://github.com/Nesvilab" target="_blank">https://github.com/Nesvilab</a>) are also provided. All raw and processed genomic data, as well as pathology reports, radiology reports, MRIs, histology slide images are accessible via the <a href="https://portal.kidsfirstdrc.org/dashboard" target="_blank">Kids First DRC (Data Resource Center)</a>.</p>
2021-02-04 | MSV000086810 | MassIVE
Project description:<a href="https://pdc.esacinc.com/pdc/browse/filters/study_name:TCGA_Colon_Cancer_Proteome" target="_blank">Explore This Study at the NCI Proteomic Data Commons</a><p><a href="http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13438.html" target="_blank">Zhang, B., et al., Nature (2014) doi:10.1038/nature13438 Published online</a></p><p>Proteomes of colon and rectal tumors previously characterized by the Cancer Genome Atlas (TCGA) were analyzed along with integrated proteogenomic analyses. Ninety-five TCGA tumor samples were used in this study from 90 patients, with 5 samples representing different portions from the same tumor. The samples originated from two TCGA cohorts: 64 are from <a href="https://portal.gdc.cancer.gov/projects/TCGA-COAD" target="_blank">Colon Adenocarcinoma (COAD)</a> samples and 31 are from the <a href="https://portal.gdc.cancer.gov/projects/TCGA-READ" target="_blank">Rectum Adenocarcinoma (READ)</a> collection. The primary data from the liquid chromatography-tandem mass spectrometry (LC-MS/MS) global proteomic profiling of each tumor sample is associated with a data set in the table below. Three protein assemblies are provided from different protein database searches.</p><p>TCGA_VU_N95<br/>This assembly reflects the 95 TCGA samples for 90 tumors, spanning three search engines (MS-GF+, MyriMatch, and Pepitome), employing a standard RefSeq database and NIST spectral library.</p><p>TCGA_VU_N95_Custom<br/>The Custom assembly represents the same samples, the sequence database has been augmented with nonsynonymous sequence variants detected by TCGA.<br/></p><p>TCGA_VU_N95-Normal_VU_N60<br/>The third assembly contains the searches of the 95 TCGA samples employed in the first assembly alongside the 60 normal colons analyzed by Vanderbilt University as a control, employing the same three search engines, a standard RefSeq database, and a NIST spectral library.</p><p>TCGA_Colorectal_Cancer_proBAM_PSM_genome_mapping_files<br/>Peptide spectrum matches from the TCGA_VU_N95_Custom IDPicker3 protein assembly were converted to protein BAM (proBAM) format for visualization, available in the metadata folder below.</p><p>COAD tumor sample genomic data can be downloaded from <a href="https://portal.gdc.cancer.gov/legacy-archive/search/f?filters=%7B%22op%22:%22and%22,%22content%22:%5B%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.program.name%22,%22value%22:%5B%22TCGA%22%5D%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.project_id%22,%22value%22:%5B%22TCGA-COAD%22%5D%7D%7D%5D%7D" target="_blank">here</a>.<br/>READ tumor sample genomic data can be downloaded from <a href="https://portal.gdc.cancer.gov/legacy-archive/search/f?filters=%7B%22op%22:%22and%22,%22content%22:%5B%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.program.name%22,%22value%22:%5B%22TCGA%22%5D%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.project_id%22,%22value%22:%5B%22TCGA-READ%22%5D%7D%7D%5D%7D" target="_blank">here</a>.<br/></p><p>Normal colon epithelium sample mass spectrometry data can be downloaded from <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S019" target="_blank">here</a>.<br/>Mass spectrometry data for comparison and reference (CompRef) sample standards run with this study can be downloaded from <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S017" target="_blank">here</a>.<br/>Peptide-Spectrum-Matches and Protein Reports from the CPTAC Common Data Analysis Pipeline (CDAP) can be downloaded from <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S016" target="_blank">here</a>.<br/>Network analysis of this study can be viewed at the NetGestalt CRC Portal <a href="http://www.netgestalt.org/index.html" target="_blank">here</a>.<br/><br/>This work was accomplished by the Proteome Characterization Center (PCC) at Vanderbilt University led by Dr. Daniel C. Liebler.</p><ul><li>Dataset imported into MassIVE from <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S022">https://cptac-data-portal.georgetown.edu/cptac/s/S022</a> on 08/26/19</li><li>Dataset source: <a href="https://pdc.esacinc.com/pdc/browse/filters/study_name:TCGA_Colon_Cancer_Proteome" target="_blank">https://pdc.esacinc.com/pdc/browse/filters/study_name:TCGA_Colon_Cancer_Proteome</a></li></ul>
2019-08-26 | MSV000084238 | MassIVE
Project description:<a href="https://pdc.esacinc.com/pdc/browse/filters/study_name:TCGA_Colon_Cancer_Proteome" target="_blank">Explore This Study at the NCI Proteomic Data Commons</a><p>The goal of the CPTAC, TCGA Cancer Proteome Study of Colorectal Tissue is to analyze the proteomes of TCGA tumor samples that have been comprehensively characterized by molecular methods (<a href="http://www.ncbi.nlm.nih.gov/pubmed/22810696" target="_blank">Cancer Genome Atlas Network, Nature 2012</a>).</p><p>Ninety-five TCGA tumor samples were used in this study from 90 patients, with 5 samples representing different portions from the same tumor. The samples originated from two TCGA cohorts: 64 are from <a href="https://portal.gdc.cancer.gov/projects/TCGA-COAD" target="_blank">Colon Adenocarcinoma (COAD)</a> samples and 31 are from the <a href="https://portal.gdc.cancer.gov/projects/TCGA-READ" target="_blank">Rectum Adenocarcinoma (READ)</a> collection. The primary data from the liquid chromatography-tandem mass spectrometry (LC-MS/MS) global proteomic profiling of each tumor sample is associated with a data set in the table below. This work was accomplished by the Proteome Characterization Center (PCC) at Vanderbilt University led by Dr. Daniel C. Liebler. Clinical data files contain both the human readable TCGA bar codes and the UUIDs for each sample.</p><p>Complete Data Analysis from Vanderbilt University as published in Nature (Zhang, B., et al., Nature (2014) doi:10.1038/nature13438 Published online) is available <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S022">here</a>.</p><p>Data available on this study page (peptide spectrum matches and protein reports) are from the CPTAC Common Data Analysis Pipeline.</p><p>COAD tumor sample genomic data can be downloaded from <a href="https://portal.gdc.cancer.gov/legacy-archive/search/f?filters=%7B%22op%22:%22and%22,%22content%22:%5B%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.program.name%22,%22value%22:%5B%22TCGA%22%5D%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.project_id%22,%22value%22:%5B%22TCGA-COAD%22%5D%7D%7D%5D%7D" target="_blank">here</a>.<br/>READ tumor sample genomic data can be downloaded from <a href="https://portal.gdc.cancer.gov/legacy-archive/search/f?filters=%7B%22op%22:%22and%22,%22content%22:%5B%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.program.name%22,%22value%22:%5B%22TCGA%22%5D%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.project_id%22,%22value%22:%5B%22TCGA-READ%22%5D%7D%7D%5D%7D" target="_blank">here</a>.<br/><br/>Colon tissue samples (ascending and descending) were obtained from 30 patients. Each sample was analyzed with label free global proteomic profiling. These colon samples, while derived from colon cancer subjects, did not contain tumor. Samples were obtained from the <a href="http://www.vicc.org/jimayersinstitute" target="_blank">Jim Ayers Institute for Precancer Detection and Diagnosis.</a> Data sets below are labeled with the patient identification number and contain data for both ascending and descending tissue samples. Data from colon tumor samples are available in the <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S016" target="_blank">TCGA Colorectal Cancer study</a>.</p><ul><li>Dataset imported into MassIVE from <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S016">https://cptac-data-portal.georgetown.edu/cptac/s/S016</a> and <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S019">https://cptac-data-portal.georgetown.edu/cptac/s/S019</a> on 06/23/16</li><li>Dataset source: <a href="https://pdc.esacinc.com/pdc/browse/filters/study_name:TCGA_Colon_Cancer_Proteome">https://pdc.esacinc.com/pdc/browse/filters/study_name:TCGA_Colon_Cancer_Proteome</a></li></ul>
2016-06-23 | MSV000079852 | MassIVE